Key Highlights

  • Revenue was USD 6.3 million versus USD 12.8 million a year earlier.
  • Net loss was USD 5.7 million, or USD 0.03 per share.
  • Research and development expense rose to USD 2.5 million from USD 0.8 million.
  • Nine-month Revenue rose to USD 31.4 million from USD 28.0 million.

Revenue Halves on Lower System Sales

SS Innovations International, Inc. (NASDAQ:SSII) reported third-quarter total revenue of USD 6,331,061 versus USD 12,829,349, compared with an estimated USD 15.10 million. System sales were USD 4,720,096 versus USD 11,705,375, instruments sales were USD 1,039,939 versus USD 854,440, warranty sales were USD 555,127 versus USD 244,399 and Lease income was USD 15,899.

Cost of revenue was USD 3,223,059 versus USD 6,664,413, leaving Gross Profit of USD 3,108,002 versus USD 6,164,936.

Lease income of USD 15,899 is the smallest revenue line, while system sales remain the largest despite the decline. Cost of revenue fell in line with sales, and the filing lists revenue by geographic region in a separate table.

Spending and Net Loss

Research and development expense rose to USD 2,500,826 from USD 786,319, Stock Compensation expense was USD 2,153,984 versus USD 2,095,163 and selling, general and administrative expense fell to USD 4,150,363 from USD 4,821,552. Total operating expenses were USD 9,164,422 versus USD 8,000,207, and the loss from operations was USD 6,056,420 versus USD 1,835,271.

Net loss was USD 5,749,389 versus USD 3,717,964, or USD 0.03 per share versus USD 0.02, compared with an estimated loss of USD 0.01. Interest expense was USD 454,549 and an income tax expense of USD 204,259 compared with a tax benefit of USD 1,847,059 a year earlier.

The weighted average basic share count was 200,377,964 versus 193,589,845, and diluted shares were 209,651,802 versus 202,856,501.

Nine-Month Results

For the nine months, total revenue was USD 31,413,961 versus USD 27,950,264, cost of revenue was USD 15,835,963 versus USD 14,783,062 and gross profit was USD 15,577,998. Net loss was USD 12,025,620 versus USD 9,656,008, or USD 0.06 per share versus USD 0.05, on 198,856,670 weighted average basic shares.

The nine-month net loss compares with USD 9,656,008 a year earlier, and the weighted average diluted share count was 208,130,508.

Gross profit for the nine months of USD 15,577,998 compares with USD 13,167,202 a year earlier.

Business and Balance Sheet

The company says it is focused on "designing, Manufacturing and Marketing an advanced, next-generation and affordable surgical robotic system" called the SSi Mantra, along with instruments and accessories. Cash and cash equivalents were USD 8,113,767 versus USD 3,206,406 at December 31, 2025, with restricted cash of USD 10,121,321, and total liabilities were USD 46,566,800 versus USD 36,007,966.

Total stockholders' Equity was USD 49,940,611 versus USD 38,218,251, and inventory was USD 22,071,213 versus USD 17,064,002. The filing describes a Working Capital surplus in its Going Concern note and lists conditions that raise substantial doubt about the company's ability to continue as a going concern.

Accounts receivable, net, were USD 16,764,399 versus USD 12,398,542, total current Assets were USD 70,629,839 versus USD 48,773,423 and additional paid-in capital was USD 121,383,836.

Accumulated Deficit was USD 67,815,554 versus USD 55,789,934, accumulated other comprehensive loss was USD 4,547,638 and prepaid expenses and other current assets were USD 13,559,139 versus USD 10,166,823. Common shares outstanding were 200,488,427 versus 194,165,141.